M. Zheng

发表

Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials

B. Strober, M. Gooderham, A. Blauvelt, 2022, SKIN The Journal of Cutaneous Medicine.